Alzheimer’s Disease and Diabetes Mellitus in Comparison: The Therapeutic Efficacy of the Vanadium Compound
Alzheimer’s disease (AD) is an intractable neurodegenerative disease that leads to dementia, primarily in elderly people. The neurotoxicity of amyloid-beta (Aβ) and tau protein has been demonstrated over the last two decades. In line with these findings, several etiological hypotheses of AD have bee...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/21/11931 |
| _version_ | 1797512399353282560 |
|---|---|
| author | Zhijun He Guanying You Qiong Liu Nan Li |
| author_facet | Zhijun He Guanying You Qiong Liu Nan Li |
| author_sort | Zhijun He |
| collection | DOAJ |
| description | Alzheimer’s disease (AD) is an intractable neurodegenerative disease that leads to dementia, primarily in elderly people. The neurotoxicity of amyloid-beta (Aβ) and tau protein has been demonstrated over the last two decades. In line with these findings, several etiological hypotheses of AD have been proposed, including the amyloid cascade hypothesis, the oxidative stress hypothesis, the inflammatory hypothesis, the cholinergic hypothesis, et al. In the meantime, great efforts had been made in developing effective drugs for AD. However, the clinical efficacy of the drugs that were approved by the US Food and Drug Association (FDA) to date were determined only mild/moderate. We recently adopted a vanadium compound bis(ethylmaltolato)-oxidovanadium (IV) (BEOV), which was originally used for curing diabetes mellitus (DM), to treat AD in a mouse model. It was shown that BEOV effectively reduced the Aβ level, ameliorated the inflammation in brains of the AD mice, and improved the spatial learning and memory activities of the AD mice. These finding encouraged us to further examine the mechanisms underlying the therapeutic effects of BEOV in AD. In this review, we summarized the achievement of vanadium compounds in medical studies and investigated the prospect of BEOV in AD and DM treatment. |
| first_indexed | 2024-03-10T06:01:16Z |
| format | Article |
| id | doaj.art-ff715f596427464bb9e546beb632fb9a |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T06:01:16Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-ff715f596427464bb9e546beb632fb9a2023-11-22T21:00:11ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-11-0122211193110.3390/ijms222111931Alzheimer’s Disease and Diabetes Mellitus in Comparison: The Therapeutic Efficacy of the Vanadium CompoundZhijun He0Guanying You1Qiong Liu2Nan Li3College of Life Sciences and Oceanography, Shenzhen University, Shenzhen 518055, ChinaCollege of Life Sciences and Oceanography, Shenzhen University, Shenzhen 518055, ChinaCollege of Life Sciences and Oceanography, Shenzhen University, Shenzhen 518055, ChinaCollege of Life Sciences and Oceanography, Shenzhen University, Shenzhen 518055, ChinaAlzheimer’s disease (AD) is an intractable neurodegenerative disease that leads to dementia, primarily in elderly people. The neurotoxicity of amyloid-beta (Aβ) and tau protein has been demonstrated over the last two decades. In line with these findings, several etiological hypotheses of AD have been proposed, including the amyloid cascade hypothesis, the oxidative stress hypothesis, the inflammatory hypothesis, the cholinergic hypothesis, et al. In the meantime, great efforts had been made in developing effective drugs for AD. However, the clinical efficacy of the drugs that were approved by the US Food and Drug Association (FDA) to date were determined only mild/moderate. We recently adopted a vanadium compound bis(ethylmaltolato)-oxidovanadium (IV) (BEOV), which was originally used for curing diabetes mellitus (DM), to treat AD in a mouse model. It was shown that BEOV effectively reduced the Aβ level, ameliorated the inflammation in brains of the AD mice, and improved the spatial learning and memory activities of the AD mice. These finding encouraged us to further examine the mechanisms underlying the therapeutic effects of BEOV in AD. In this review, we summarized the achievement of vanadium compounds in medical studies and investigated the prospect of BEOV in AD and DM treatment.https://www.mdpi.com/1422-0067/22/21/11931vanadiumbis(ethylmaltolato)oxidovanadium (IV) (BEOV)diabetes mellitus Alzheimer’s diseaseperoxisome proliferator-activated receptor (PPARγ) |
| spellingShingle | Zhijun He Guanying You Qiong Liu Nan Li Alzheimer’s Disease and Diabetes Mellitus in Comparison: The Therapeutic Efficacy of the Vanadium Compound International Journal of Molecular Sciences vanadium bis(ethylmaltolato)oxidovanadium (IV) (BEOV) diabetes mellitus Alzheimer’s disease peroxisome proliferator-activated receptor (PPARγ) |
| title | Alzheimer’s Disease and Diabetes Mellitus in Comparison: The Therapeutic Efficacy of the Vanadium Compound |
| title_full | Alzheimer’s Disease and Diabetes Mellitus in Comparison: The Therapeutic Efficacy of the Vanadium Compound |
| title_fullStr | Alzheimer’s Disease and Diabetes Mellitus in Comparison: The Therapeutic Efficacy of the Vanadium Compound |
| title_full_unstemmed | Alzheimer’s Disease and Diabetes Mellitus in Comparison: The Therapeutic Efficacy of the Vanadium Compound |
| title_short | Alzheimer’s Disease and Diabetes Mellitus in Comparison: The Therapeutic Efficacy of the Vanadium Compound |
| title_sort | alzheimer s disease and diabetes mellitus in comparison the therapeutic efficacy of the vanadium compound |
| topic | vanadium bis(ethylmaltolato)oxidovanadium (IV) (BEOV) diabetes mellitus Alzheimer’s disease peroxisome proliferator-activated receptor (PPARγ) |
| url | https://www.mdpi.com/1422-0067/22/21/11931 |
| work_keys_str_mv | AT zhijunhe alzheimersdiseaseanddiabetesmellitusincomparisonthetherapeuticefficacyofthevanadiumcompound AT guanyingyou alzheimersdiseaseanddiabetesmellitusincomparisonthetherapeuticefficacyofthevanadiumcompound AT qiongliu alzheimersdiseaseanddiabetesmellitusincomparisonthetherapeuticefficacyofthevanadiumcompound AT nanli alzheimersdiseaseanddiabetesmellitusincomparisonthetherapeuticefficacyofthevanadiumcompound |